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Methods for identifying physiologically relevant T-cell epitopes are critically important for development of 
vaccines and the design of therapeutic proteins. As the number of proteins that are being evaluated for pu-
tative immunogenicity expands, rapid and accurate tools are in great demand. Several methods to identify 
T-cell epitopes have been developed, the most recent of which is a cell free system consisting of a minimal 
set of proteases incubated with HLA DRB1*0101, HLA-DM and whole antigen. Isolation and sequencing of 
the HLA bound peptides using mass spectrometry allows for the prospective identification of immuno-
dominant T-cell epitopes. 
Results 
We present here, a comparison of this cell free in vitro antigen processing system to an immunoinformatics 
approach using the EpiMatrix algorithm. Our comparison reveals that in addition to identifying a similar set 
of epitopes to the cell-free system, the immunoinformatics approach prospectively identifies more HLA-
DRB1*0101 epitopes and can simultaneously analyze multiple HLA alleles. 
Conclusions 
Although the cell-free system incorporates antigen processing and MHC binding, the immunoinformatics 
approach identifies many validated epitopes with a very high degree of accuracy and can be performed 
much faster with far fewer resources. 
Background  
 
Methods for the prospective identification of physiologi-
cally relevant T-cell epitopes are critically important for 
development of vaccines and for the design of therapeu-
tic proteins. A cell free system (CFS) for prospectively 
identifying T-cell epitopes from whole antigens was re-
cently described and applied to the identification of influ-
enza epitopes [1]. As described by Hartman et al. in their 
publication, CFS epitope mapping was performed by pre-
incubating whole antigens with HLA-DRB1*0101 and 
HLA-DM, and then exposing the mixture of antigen and 
HLA DR/DM to a minimal set of proteases, followed by 
isolation and sequencing of the HLA-bound peptides 
using mass spectrometry. The CFS was initially validated 
using two model antigens (HA1 from influenza A/
Texas/1/77 and type II collagen) as positive controls and 
then applied prospectively for the discovery of new HLA
-DRB1*0101 immunodominant epitopes from a recombi-
nant liver-stage antigen of malaria falciparum (LSA-
NRC) and HA1 from H5N1 influenza (Viet Nam).  
The publication of the CFS method provided an opportu-
nity for comparing a purely immunoinformatics approach 
based entirely on MHC binding affinity (EpiMatrix) to an 
in vitro system that involves both antigen processing and 
presentation [2]. We hypothesized that predicted MHC 
binding (as performed in silico) would provide results 
that were at least equivalent to the more laborious CFS 
approach. As the identification of T cell epitopes using 
the CFS approach. requires a significant amount of labo-
ratory effort, reagents, and specific expertise in the use of 
MALDI mass-spectrometry, the immunoinformatics ap-
proach might, in addition, offer significant time and cost 
savings. As is described here, our detailed comparison 
reveals that the immunoinformatics method correctly 
identified four of the six epitopes identified by the CFS 
method, at lower cost and with greater time efficiency, 
and, in addition, identified other potential epitopes that 
appear to have been missed by the CFS. Neither of the 
two CFS epitopes that were missed by EpiMatrix were 
validated in follow up assays. In the brief report below, 
we provide a detailed comparison of the in silico ap-
proach using EpiMatrix and the CFS approach, in terms 
of epitopes identified and the relative speed, effort re-




CFS reductionist method 
The CFS approach to finding immunodominant epitopes, 
as published in reference 1, is described here for com-
parison with the EpiMatrix method. The cell free system 
(CFS) is restricted to evaluations of a single HLA at a 
1 EpiVax, Inc., Providence, RI, USA 
2 Institute for Immunology and Informatics, University of Rhode Island, 
Providence, RI, USA 
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time. The assay requires combining a minimal set of 
components for antigen processing (full length antigen, 
human MHC Class II HLA-DRB1*0101, HLA-DM, and 
Cathepsins S, B, and H) under both endosomal and ly-
sosomal conditions. Hartman et al. describe the applica-
tion of the CFS method to four proteins: (1) an artificial 
construct of influenza H1N1 (A/PR/8/34) HA with a sin-
gle, well-known DR1-restricted epitope (A/Texas/1/77 
HA306-318) appended to the C-terminus; (2) Collagen type 
II; (3) influenza H5N1 (A/Vietnam/1203/2004) HA and 
(4) Liver stage malaria antigen. The resulting peptide-
DR1 complexes were isolated by immunoprecipitation 
and the bound peptides were eluted under acidic condi-
tions. These eluted peptides were then analyzed on a ma-
trix-assisted laser desorption ionization (MALDI) mass 
spectrometer.  
Results for the CFS method were obtained using a single 
allele (HLA-DRB1*0101) [1]. The eluted epitopes were 
validated in vitro using T cell proliferation, cytokine in-
duction, tetramer staining, or some combination of the 
three following immunization of HLA-DRB1*0101 mice 
with the whole protein antigen.  
For example, recombinant HA1 (rHA1), engineered to 
include a published epitope, was incubated in the cell 
free system. After isolating HLA DRB1*0101 com-
plexes, the genetically-linked A/Texas/1/77 known im-
munodominant epitope and only one other peptide (A/
PR/8/34 HA298-317) were eluted from peptide-DR1 com-
plexes. T cell proliferation assays using peripheral blood 
mononuclear cells (PBMC) obtained from HLA 
DRB*0101 transgenic mice immunized with rHA1 
showed a strong dose dependent response to the A/
Texas/1/77 single epitope identified by the cell free assay 
and a weaker but still significant response to the A/
PR/8/34 peptide. The sum of proliferative responses (ex 
vivo) to these two epitopes approached the magnitude of 
the response to whole rHA1.  
As a second example, bovine type II collagen (CII) was 
used to test the epitope identification system. CII is a 
major component of cartilage and is the main suspected 
auto-antigen in rheumatoid arthritis in DR1+ individuals 
[4]. A core DR1 restricted immunodominant epitope, 
CII282-289, has been identified in CII in mouse studies. 
Following enzymatic digestion and incubation in the 
CFS, one peptide was eluted, CII273-305, as well as vari-
ants of that peptide that share the same core epitope. Pro-
liferation studies performed with T cells from CII-
immunized mice validated the eluted CII273-305 epitope.  
The CFS was also used to prospectively identify immu-
nodominant DR1 epitopes from HA1 protein of influenza 
A/Vietnam/1203/2004 (H5N1) and LSA-NRC, a recom-
binant modified version of a protein expressed exclu-
sively in malaria-infected hepatocytes at a preerythro-
cytic stage, which was designed as a vaccine against 
preerythrocytic stage malaria. Several new epitopes 
(Figure 1) were identified in these previously unmapped 
proteins and subsequently validated in T cell assays fol-
lowing immunization of HLA-DR1 transgenic mice with 





The sequences of the four antigens evaluated in the CFS 
were obtained from GenBank and then analyzed using 
EpiMatrix [EpiVax, Providence USA]. Standard criteria 
(EpiMatrix score in top 5% of scores on a Z scale) were 
used for epitope identification [2]. A list of the EpiMatrix
-predicted HLA DRB1*0101 epitopes was created and 
compared to the epitopes identified by the CFS. EpiMa-
trix prospectively identified four of the six epitopes that 
were identified by the CFS (67%), and one epitope from 
each of the antigens; I/C-CII3, I/C-PR1, I/C-Tex1, and I/
C-LSA2 (Table 1). These epitopes are shown at the inter-
section of the Venn diagram in Figure 1 and labelled I/C 
to denote that they were identified by both the Immu-
noinformatics (I) and the CFS (C) approaches.  
All four I/C epitopes scored among the top 5 HLA 
DRB1*0101 EpiMatrix scores for the antigens (the Epi-
Matrix rank is indicated by the numerical suffix in Table 
1 and Figure 1). Both of the “C” epitopes, which were 
discovered by the CFS but not by EpiMatrix, scored 
within the top 10% of EpiMatrix scores, which is below 
the top 5% cut-off that would normally be used for the 
selection of T cell epitopes by EpiMatrix analysis. We 
note that one of these epitopes, selected by the CFS (C-
VN45) has been reported to be HLA DRB1*0401- and 
HLA DRB1*1101-restricted according to IEDB, but not 
HLA DRB1*0101-restricted. Consistent with the IEDB-
reported findings, DRB1*0401 and DRB1*1101 EpiMa-
trix scores for this epitope are in the top 1% of predicted 
binders. The second epitope identified by the CFS and 
not by EpiMatrix (C-LSA11) fell just below the EpiMa-
trix cut-off for a positive score (1.58, rather than 1.64, 
see Methods).  
 
Figure 1 - EpiMatrix prospectively identifies more potential epitopes 
than the CFS. 
Epitopes identified by the CFS are labelled C, epitopes discovered by 
Immunoinformatics are labelled I and epitopes discovered by both are 
labelled I/C; the rank in the HLA DR1 EpiMatrix analysis for the antigen is 
indicated by the number 1-5; note that only one epitope from influenza A 
Texas was used (recombinantly fused to the PR protein) rather than the 
whole protein and therefore this single epitope is given the first rank (I/C-
Tex1). 
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As compared to the CFS, the EpiMatrix immunoinfor-
matics approach identified many more prospective epi-
topes for each of the antigens. Performing the analysis as 
described here, a total of 13 epitopes were identified 
based on their HLA DRB1*0101 score: these included 
the three highest-scoring epitopes for each of four anti-
gens that were evaluated by the CFS and the one high-
scoring HLA DRB1*0101 epitope from A/Texas (only 
one published epitope was included in the rHA protein 
tested in the CFS). Of these 13 epitopes, eight (62%) 
were previously confirmed as human T cell epitopes, 
according to IEDB; validation is not yet recorded the 
remaining five epitopes.  
 
Detailed comparison of CFS and EpiMatrix results 
 
Epitope sequences identified by both the CFS and Epi-
Matrix method were cross-referenced against the Im-
mune Epitope Database (IEDB) of published T cell epi-
topes and MHC ligands using the substring parameter. 
Further, all T cell responses and MHC binding results 
available on IEDB were compiled for each input antigen. 
If IEDB is taken as the reference standard for validation 
of epitopes predicted by either method, EpiMatrix pro-
spectively identified five more „validated‟ epitopes that 
the CFS method did not identify. CFS identified two epi-
topes that were not identified by EpiMatrix, and although 
these are published in IEDB, they have been published 
for alternative alleles. If more stringent criteria are ap-
plied, (restriction by HLA DRB1*0101 and publication 
in IEDB), EpiMatrix correctly identified three of the 
three (100%) HLA DRB1*0101-restricted epitopes. This 
significant reduction is due in part to the limited HLA-
restriction references available on IEDB; of the four test 
antigens, only H5N1 Vietnam had references qualified as 
HLA-DRB1*0101-restricted. As we will discuss in 
greater detail below, the single HLA DRB1*0101-
restricted epitope prospectively identified by the CFS (I/
C-CII5), was only validated as a result of querying the 
EpiMatrix-identified core.  
 
Influenza PR antigen. The single PR epitope that was 
identified by both the CFS and EpiMatrix, I/C-PR1, was 
ranked first of all PR-derived HLA DRB1*0101 epitopes 
by EpiMatrix, and was extracted from the same amino 
acid locus (306-318) as the influenza HA epitope control 
peptide (I/C-Tex1) that was fused to the A/PR/8/34 anti-
gen. The two epitopes also identified by EpiMatrix have 
high DRB1*0101 scores (I/C-PR1 and I/C-Tex1) and 
contain an epitope bar (or EpiBar) [6,7], a feature that is 
often present in promiscuous epitopes [5], and that has 
been associated with immunogenicity in human studies 
[8,9]. This important feature of promiscuous, immuno-
genic epitopes is not detectable using the CFS. EpiMatrix 
also identified two additional epitopes in influenza A/
PR/8/34 HA (Table 1).  
Influenza A Viet Nam. When the full length HA1 from 
H5N1 A/Vietnam/1203/2004 was analyzed in the CFS, 
two unique peptide species were identified; both shared 
the same core sequence (C-VN45). The authors selected 
the shorter of these two peptides (HA259-274) to test for 
immunodominance in T cell proliferation assays, cyto-
kine production assays, and tetramer staining assays. 
EpiMatrix analysis shows that the shorter HA most likely 
has a truncated terminal HLA DRB1*0101 HLA binding 
motif. The peptide only has one EpiBar at the C-terminal 
end of the sequence and the N-terminal end of the pep-
tide, which is devoid of predicted HLA binding motifs, 
would interfere with binding, in vitro, and with immuno-
genicity. The properly centered peptide would have been 
identified prospectively using EpiMatrix.  
Three other epitopes were predicted by EpiMatrix in the 
same protein to be better HLA DRB1*0101 binders, but 
they were not identified by the CFS. All three have been 
experimentally validated and published; only one was 
confirmed for HLA DRB1*0101. Based on the fact that 
the third-ranked EpiMatrix epitope is published and 
found to be an HLA DRB1*0101 epitope in IEDB, the 
other two (ranked 1 and 2) are equally likely if not more 
likely to be HLA DRB1*0101-restricted, however this 
would have to be tested prospectively in T cell assays as 
was done for the CFS epitopes.  
Collagen. It is notable that the single collagen epitope (I/
C-CII5) identified by the CFS was also confirmed by 
EpiMatrix. It was the 5th ranked peptide for HLA 
DRB1*0101, which is not unexpected considering the 
greater length of the CII sequence compared to other 






Table 1 - Epitope Comparison 
Summary of epitopes identified by EpiMa-
trix and the CFS. In the case of I/C-PR1, I/
C-Tex1, and C-VN45, multiple overlap-
ping peptides were eluted in the CFS; 
those peptides sharing the same core 9-mer 
identified by EpiMatrix are considered one 
epitope. Variable flanking resides are 
indicated in grey text. Refer to Figure 1 for 
nomenclature and annotation. 
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maximum DR1 EpiMatrix score of 2.66, putting it in the 
top 1% of peptides expected to bind to DR1, a rank that 
would have normally led to selection by EpiMatrix. The 
sequence of the CFS eluted peptide CII273-305 contains the 
same epitope that is predicted by EpiMatrix, however its 
sequence is elongated and the probable HLA binding 
motif is almost obscured by the extended flanks that were 
eluted with the core sequence. When queried against the 
IEDB, the CFS-eluted sequence returned no results, 
whereas the EpiMatrix-identified core sequence was pub-
lished as a DRB1*0101-restriced epitope. In other words, 
immunoinformatics analysis using EpiMatrix can rapidly 
and accurately identify a core HLA binding epitope, 
whereas the CFS does not. EpiMatrix identified three 
additional epitopes in Cll that are likely to be immuno-
genic (ranked 1, 2, and 3). One was previously reported 
in IEDB but not confirmed in HLA transgenic mice nor 
in human T cell assays.  
 
Malaria LSA. Finally, the single LSA epitope identified 
by both the Immunoinformatics approach and the CFS 
method contains a strong EpiMatrix-scoring peptide, and 
was the only LSA epitope to be validated in T cell as-
says. The weaker LSA epitope (C-LSA11) was also iden-
tified by the immunoinformatics approach, but the Epi-
Matrix score was slightly below the normal cut off for 
selection. Two additional epitopes, I-LSA1 and I-LSA3 
were identified using EpiMatrix, of which one (I-LSA1) 
is found in IEDB for an unreported Class II HLA allele. 
 
Discussion  
The CFS method described by Hartman et al. is a novel 
approach for identification of T cell epitopes that in-
volves a significant amount of effort, reagents, and 
highly technical expertise in the use of MALDI mass-
spectrometry. One advantage of CFS is that the method 
could, in theory, be applied to additional antigens and 
alleles for which immunoinformatics approaches do not 
yet exist. In comparison to the immunoinformatics ap-
proach, EpiMatrix, it appears to be both time- and cost-
intensive. Many of the same epitopes are identified using 
the two approaches. Additionally, previously validated 
epitopes are identified using EpiMatrix that appear to be 
missed by the CFS (when comparing CFS and EpiMatrix 
results with the IEDB database of published and vali-
dated epitopes), as are several epitopes that appear likely 
to be immunogenic based on their rank and EpiMatrix 
score. Thus antigen-processing as performed using the 
CFS may have destroyed peptides that might otherwise 
have been presented by DR1. Two epitopes were identi-
fied using the CFS that would not have been selected by 
EpiMatrix. Neither of these epitopes would qualify as 
high quality targets based on information obtained from 
IEDB. 
Epitopes identified using the CFS were not compared to 
epitopes that have already been published. Instead, in 
vivo methods were used to validate sequences. Epitopes 
were considered to be validated if, following immuniza-
tion of HLA-DRB1*0101 mice with whole antigen,        
T cells were induced to proliferate, cytokine production 
was increased, or tetramer-stained cells could be        
detected, or some combination of the three. These meth-
ods are useful for validation regardless of the epitope 
selection method – and have been used for the validation 
of T cell epitopes identified using EpiMatrix (see refer-
ences 6 and 9).  
The CFS may provide some additional information on 
epitopes that are processed (two were identified in the 
CFS that were not identified using EpiMatrix) and may 
have application to organisms with little to no informa-
tion on peptide-MHC interactions. A much more exten-
sive (and perhaps cost-prohibitive) comparison would 
have to be performed, prospectively validating the epi-
topes discovered using EpiMatrix alongside epitopes 
discovered using the CFS, before either method is proven 
to be superior to the other. At the very least, they appear 
to be somewhat complementary.  
It should be mentioned that there are a range of epitope 
prediction tools available, however each tool may pro-
vide slightly different results [3]. For example, when 
analyzing the sequences from H5N1 Vietnam and rLSA-
1, both of which contain CFS-only epitopes, (Figure 1) 
with NetMHCII [10], an alternative epitope prediction 
tool, NetMHCII predicted the H5N1 Vietnam epitope but 
the rLSA-1 epitope was still not predicted. NetMHCII 
predicted similar epitopes to EpiMatrix for the proteins 
included in this analysis (data not shown) with the best 
scoring EpiMatrix epitopes centered within the sequences 
all of the strong binders predicted by NetMHCII. 
NetMHCII does not further delineate the optimal epitope 
when using its default peptide length of 15 amino acids 
(http://www.cbs.dtu.dk/services/NetMHCII/) .  
Immunoinformatics provides a rapid means of analyzing 
protein sequences for multiple HLA alleles at the same 
time. EpiMatrix prospectively identified more HLA-
DRB1*0101 epitopes than the CFS, of which almost all 
are present in IEDB. In addition to providing an analysis 
of multiple alleles at once (not just HLA DRB1*0101) 
and highlighting promiscuous epitopes (data not shown, 
references 2 and 3 provide examples), the immunoinfor-
matics approach can be performed at a fraction of the 
time and cost (one day, no reagents, versus multiple 
weeks, technician time, in vitro reagents, and MALDI 
mass spectrometer costs). Thus immunoinformatics ap-
proaches with algorithms such as EpiMatrix provide a 
clear cost and time advantage over CFS. 
As the number of proteins that are being evaluated for 
putative immunogenicity expands, rapid, inexpensive and 
accurate tools are in great demand. The time and effort 
involved in prospectively identifying peptides from a 
single protein for a single allele were not reported for this 
study. Based on rough estimates for the costs, the immu-
noinformatics method can be performed in less than 
1/20th of the time and for 1/100th of the cost of the cell 
free method. If one is to compare the cost of equipment 
that would be necessary for these two methods (a single 
internet accessible computer vs. a fully functional lab 
with mass spectrometry and protein production          
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capabilities), this gap grows exponentially wider.  
 
Conclusions  
Adding antigen-processing to epitope selection in vitro 
does not improve prospective class II antigen identifica-
tion. In this comparison of two methods for T cell epi-
tope identification, the in vitro antigen-processing and 
MHC-elution method (CFS) obscured two of three exter-
nally validated, HLA-DRB1*0101-restricted epitopes, 
whereas the immunoinformatics approach (EpiMatrix) 
correctly identified all published epitopes restricted by 
DRB1*0101, and prospectively identified many addi-
tional epitopes that have yet to be validated. While the 
CFS approach may enable identification of epitopes from 
MHC for which there is little to no published informa-
tion, the advantages of the immunoinformatics method, 
which include a very high degree of accuracy, high 




Proteins analyzed by EpiMatrix are parsed into 9-mers 
that overlap each other by 8 amino acids. Each of these 9
-mers is then scored individually (and simultaneously) 
for predicted binding affinity against a panel of eight 
common Class II HLA alleles (DRB1*0101, *0301, 
*0401, *0701, *0801, *1101, *1301, and *1501) that 
collectively cover over 95% of the human population 
[11]. EpiMatrix scores range from approximately -3 to 
+3. Those 9-mer peptides that score 1.64 or above are 
considered to be potential epitopes. The predictions have 
been benchmarked against the „gold standard‟ set of pub-
lished epitopes, performing as well or better than other 
epitope mapping tools [3]. Typically, 5% of all nine-mer 
frames in a given protein score above 1.64; these are con-
sidered to have a significant chance of binding to HLA 
molecules with moderate to high affinity and to have a 
significant chance of being presented on the surface of 
APCs [3].  
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